Creative Biolabs Updated Solutions to Assist Anti-SARS-CoV-2 Drug Discovery
Creative Biolabs, keeping a close eye on the new SARS-CoV-2 mutants and corresponding drug development trends, recently updated its service portfolio in agreement with further SARS-CoV-2 therapeutic exploration.
New York, NY (PRUnderground) November 28th, 2022
It’s nearly 3 years since the discovery of SARS-CoV-2 in December of 2019, ever since when people around the globe began to be threatened by the culprit of a highly persistent respiratory disease—COVID-19. Seeing the emergent situation, Creative Biolabs, one of the CROs devoted to virology study and immunotherapy development, instantly responded and established a solution center exclusively serving clients in the study of SARS-CoV-2 and coronaviruses and has recently updated its service portfolio to back new therapeutic discoveries.
“SARS-CoV-2 is evolving,” commented one of the scientists specialized in coronaviruses at Creative Biolabs, “and the same should go with drug development tactics. We also noticed the rise of disappointing results regarding failed or diminished neutralization responses of vaccines under trials. The virus is indeed tricky, but we’re determined to help with the discovery of potent drugs.”
Creative Biolabs enthusiastically gets involved in vaccine discovery, specifically providing service to support the development of SARS-CoV-2 live attenuated vaccines that have proven efficacy not only in preventive vaccines but have also received tremendous expectation in therapeutic usages.
“Another part of our efforts is antiviral drug discovery,” added the scientist, “which is conducted based upon high-throughput screening like targeted screening, diversity and high-content screening, and RNAi, on large and full-spectrum libraries of approved drugs and pharmacologically active compounds, inhibitors, proteins, and peptides.”
Two “popular” antiviral agents under heated research are neutralizing antibodies and peptides, both of which can find corresponding solutions at Creative Biolabs. According to the specialist, the fusion peptide (EK1) and ACE2-based peptide for SARS-CoV-2 treatment received much attention recently.
“Based upon our rich experience gained through SARS and MERS pandemics, we’re fully spirited in discovering effective measurements to curb the infection and finding ways to end this harsh circumstance.”
Visit https://sars-cov-2.creative-biolabs.com/ to learn more about Creative Biolabs’ capabilities.
About Creative Biolabs
Creative Biolabs is a CRO working dedicatedly in the field of new drug discovery and is famous for its one-stop solution, covering the fundamental preclinical drug discovery pipeline initiating from target identification all the way to PK and PD validations. Since the outbreak of SARS-CoV-2 in 2019, Creative Biolabs has been keeping a close eye on the epidemic trend, actively reacting to any new emerging variant, aiming to provide the most up-to-date strategies for its customers working on antiviral drug discovery. A group of scientists from Creative Biolabs is participating in the Antibody Engineering & Therapeutics (US) 2022 in December, where their specialty in antibody discovery, engineering, and manufacturing will be presented.